Bridges Investment Management Inc. grew its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 173.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 252,646 shares of the healthcare product maker’s stock after purchasing an additional 160,120 shares during the period. Bridges Investment Management Inc.’s holdings in Abbott Laboratories were worth $26,252,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently made changes to their positions in the company. Unique Wealth Strategies LLC bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $28,000. Transcendent Capital Group LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $29,000. Richardson Financial Services Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $29,000. Redmont Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the first quarter worth about $30,000. Finally, True Wealth Design LLC boosted its holdings in shares of Abbott Laboratories by 1,677.8% in the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after buying an additional 302 shares during the period. Institutional investors own 75.18% of the company’s stock.
Insider Activity at Abbott Laboratories
In other news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the transaction, the chief executive officer now owns 220,059 shares of the company’s stock, valued at $25,617,068.19. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.10% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Price Performance
Shares of ABT opened at $114.15 on Friday. The firm has a market cap of $198.58 billion, a PE ratio of 35.56, a PEG ratio of 2.90 and a beta of 0.72. The firm’s 50 day moving average price is $110.32 and its 200 day moving average price is $108.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.04. The firm had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.08 earnings per share. As a group, research analysts expect that Abbott Laboratories will post 4.66 EPS for the current fiscal year.
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- 3 REITs to Buy and Hold for the Long Term
- Prepare for a Silver Surge: Best Mining Stocks to Watch Now
- How to Use the MarketBeat Stock Screener
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Learn Technical Analysis Skills to Master the Stock Market
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.